EOLO PHARMA

EOLO Pharma focuses on developing drugs targeting the molecular and cellular basis of inflammation-related diseases (e.g. Type II diabetes, autoimmune, metabolic syndrome, hypertension, atherosclerosis, etc) creating disruptive therapies for the treatment and prevention of the leading causes of death worldwide. EOLO Pharma holds global patents based on over 15 years of scientific data developed by the founders. The Company has conducted preclinical trials with exceptional results. The Company was founded by a multidisciplinary team of leading scientists from the prestigious Institut Pasteur de Montevideo (the South American branch of Institut Pasteur Paris).